Starts at 16:04, couple points on Samsung.
1) They agreed to do the upfront work now with payments over 2020. Samsung’s research about leronlimab’s success must have supported such an unheard of decision.
2) CMC cost was 16M this year, 14M last. The added cost is what I focus on instead of total cost.


16:04 look like in the meantime I've been also
16:07 talking with a variety of other
16:10 potential partners for CytoDyn
16:12 because I think if we had a two drug
16:14 regimen that was a two drug once a week
16:17 regimen it would be a killer and it
16:20 would do very well and would be a huge
16:22 benefit to the HIV community and I think
16:25 other sponsors are waking up to that
16:27 idea I think there's a lot of interest
16:30 in monthly intramuscular
16:33 injections but the reality of what's
16:35 involved with patients having to go to
16:38 an office or a pharmacy and painful
16:41 monthly injection is setting in and
16:44 there are a variety of potential
16:46 compounds now that CytoDyn could
16:48 partner with I think in mono
16:51 therapy it's good I think there's a
16:53 combination when the second drug it
16:54 could be great um and I'll just stop